About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Worldwide rights to AFREZZA have been licensed to Sanofi. For more information about AFREZZA, please visit www.Afrezza.com.


Sanofi and MannKind Announce Afrezza®, the Only Inhaled Insulin, Now Available in the U.S. More >

News & Events

May 21, 2015 James S. Shannon Rejoins MannKind's Board of Directors More >
May 07, 2015 MannKind Corporation Reports 2015 First Quarter Financial Results More >
May 06, 2015 MannKind to Present at Bank of America Merrill Lynch 2015 Healthcare Conference More >